RESUMO
Factors predisposing to and associated with atherosclerosis may impact the onset and progression of Alzheimer disease (AD). The high prevalence of atherosclerosis and associated risk factors in American Indians makes them ideal subjects to test this association. We compared frequency of history of hypertension, myocardial infarction, stroke, diabetes, and high cholesterol in 34 American Indians with AD with 34 age-matched American Indian controls, and 34 age-matched whites with probable AD. We also measured waist size, height, and weight, and acquired blood for determination of plasma homocysteine and apolipoprotein E genotype. The 3 groups did not differ significantly in age or sex. History of hypertension and diabetes was significantly more common among American Indian AD patients than Indian controls or whites with AD. The 3 groups did not differ in history of stroke or myocardial infarction. Body mass index was significantly greater in both Indian groups than the white AD group. Plasma homocysteine levels were greater, but not significantly so, in the Indian AD than the Indian control group. Thus, there is preliminary evidence of a modest association between history of hypertension and diabetes and AD in a small sample of American Indians. This suggests that changes in lifestyle factors could influence the expression of AD in American Indians.
Assuntos
Doença de Alzheimer/complicações , Doença de Alzheimer/epidemiologia , Aterosclerose/complicações , Aterosclerose/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/genética , Apolipoproteína E4/genética , Aterosclerose/genética , Índice de Massa Corporal , Diabetes Mellitus/epidemiologia , Feminino , Homocisteína/sangue , Humanos , Hipertensão/epidemiologia , Indígenas Norte-Americanos , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de RiscoAssuntos
Doença de Alzheimer/tratamento farmacológico , Comportamento/efeitos dos fármacos , Cognição/efeitos dos fármacos , Nootrópicos/uso terapêutico , Piracetam/análogos & derivados , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Relações Interpessoais , Levetiracetam , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Piracetam/uso terapêutico , Resultado do TratamentoRESUMO
BACKGROUND: We report on the responsiveness of a previously validated quality-of-life scale, the Quality of Life in Late-Stage Dementia scale (QUALID), as an outcome measure in a clinical trial of two psychotropic medications. METHODS: Secondary analyses were conducted comparing outcome measures used in a randomized double-blind trial of two antipsychotics (olanzapine and risperidone) for the treatment of dementia-related behavioral symptoms. The QUALID was completed for 31 of the patients in addition to several measures of behavior-related dementia symptoms including the Neuropsychiatric Inventory, the Withdrawn Behavior subscale of the Multidimensional Observation Scale for Elderly Subjects, the Mini-Mental State Examination, and the Clinical Global Impression. Measures of safety and adverse effects included the Simpson-Angus Scale and records of specific adverse events. RESULTS: A significant positive relationship was found between QUALID score and improvement in behavioral symptoms, and a negative association was found with adverse medication effects. CONCLUSIONS: The QUALID was sensitive to both the treatment effects and the adverse effects of medication in this sample of patients.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Qualidade de Vida/psicologia , Risperidona/uso terapêutico , Transtornos do Comportamento Social/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/psicologia , Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Método Duplo-Cego , Feminino , Instituição de Longa Permanência para Idosos , Humanos , Assistência de Longa Duração , Masculino , Entrevista Psiquiátrica Padronizada , Casas de Saúde , Olanzapina , Psicometria , Risperidona/efeitos adversos , Transtornos do Comportamento Social/diagnóstico , Transtornos do Comportamento Social/psicologiaRESUMO
To determine if Alzheimer's disease (AD), its Lewy body (LB) variant (LBV), and diffuse LB disease (DLBD) are distinguishable at initial clinical evaluation, data from autopsy-confirmed AD, LBV, and DLBD were examined. No significant differences were found in age at onset, age at death, total duration of illness, duration of illness before initial visit, duration of illness from initial visit to death, or severity of illness at initial evaluation. Hallucinations and delusions were significantly more frequent for LBV and DLBD, respectively, than for AD, and falls were more frequent for DLBD than for AD. Extrapyramidal symptoms (EPS) were less frequent in neuroleptic-free AD subjects than in LB subjects; the percentage of AD patients with EPS after neuroleptic exposure was less than that among LB patients. Seizures were significantly more common for DLBD than for AD or LBV. LB dementias differed from AD at initial evaluation, with more frequent hallucinations and delusions, EPSs, and seizures, and longitudinally in neuroleptic sensitivity, but the data did not distinguish LBV from DLBD.
Assuntos
Doença de Alzheimer/diagnóstico , Encéfalo/patologia , Doença por Corpos de Lewy/diagnóstico , Idoso , Doença de Alzheimer/epidemiologia , Doenças dos Gânglios da Base/epidemiologia , Delusões/diagnóstico , Delusões/epidemiologia , Diagnóstico Diferencial , Seguimentos , Alucinações/diagnóstico , Alucinações/epidemiologia , Humanos , Doença por Corpos de Lewy/epidemiologia , Testes Neuropsicológicos , Prevalência , Convulsões/epidemiologia , Índice de Gravidade de DoençaRESUMO
Donepezil has been shown to improve aspects of cognitive functioning in persons with Alzheimer's disease (AD), but its impact on instrumental activities of daily living has received little attention. In a within-subject design, 24 community-dwelling persons with AD were treated with open-label donepezil over a 12-month period. To assess functional abilities, a brief, objective measure of instrumental activities of daily living skills was used (Texas Functional Living Scale; TFLS). Global cognitive abilities were assessed with the Mini-Mental State Examination (MMSE). Changes in TFLS and MMSE scores were much the same. Improvements on the TFLS and MMSE were seen over a 3-month period. At 12 months, both TFLS and MMSE scores declined slightly below baseline. These results support an effect of donepezil on cognitive measures and day-to-day function and also suggest that the MMSE reflects well the actual functional ability of persons with moderate AD.